EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation

Gabriella de Souza Gomes Ribeiro, Pieter Annaert, Frederico Severino Martins, Tania Marcourakis

Future Pharmacology · 23.06.2026 · 6 (3) · 34

DOI: 10.3390/futurepharmacol6030034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 23.06.2026. Verfasst von Gabriella de Souza Gomes Ribeiro und 3 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAPES, FAPESP.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: In this study, we present an analysis of ayahuasca, a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and β-carbolines, such as harmine (HRM), a reversible monoamine oxidase A (MAO-A) inhibitor that enables the oral bioavailability of DMT. CYP2D6 is a highly polymorphic enzyme associated with interindividual variability in drug exposure, but its influence on the pharmacokinetics of ayahuasca alkaloids remains poorly understood.

Methods

Using physiologically based pharmacokinetic (PBPK) modeling, we simulated scenarios for poor (PM), normal (NM), and ultra-rapid (UM) metabolizers by adjusting CYP2D6 enzyme expression for each phenotype.

Results

PMs showed increased systemic exposure to DMT (AUC +53.3%; Cmax +40.5%) and HRM (AUC +30.6%; Cmax +22.8%), while UMs exhibited reduced exposure to both compounds.

Conclusions

These findings highlight the significant impact of CYP2D6 polymorphisms on the pharmacokinetics of DMT and HRM, reinforcing the value of PBPK modeling for predicting interindividual variability and potential clinical risks.

Förderung

  • CAPES
  • FAPESP

Zitieren

APA

Ribeiro, G. D. S. G., Annaert, P., Martins, F. S., & Marcourakis, T. (2026). Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation. Future Pharmacology, 6(3), 34. https://doi.org/10.3390/futurepharmacol6030034

Vancouver

Ribeiro GDSG, Annaert P, Martins FS, Marcourakis T. Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation. Future Pharmacology. 2026;6(3):34. doi:10.3390/futurepharmacol6030034

BibTeX
@article{Ribeiro2026,
  author = {Ribeiro, Gabriella de Souza Gomes and Annaert, Pieter and Martins, Frederico Severino and Marcourakis, Tania},
  title = {Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation},
  journal = {Future Pharmacology},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {34},
  doi = {10.3390/futurepharmacol6030034}
}
Kostenlos starten →